CARGO is advancing a pipeline
of next-generation adoptive
CAR T-cell therapies for cancer

At CARGO, we are committed to developing best-in-class chimeric antigen receptor (CAR) T-cell therapies that overcome resistance and address barriers to access so that more patients benefit from potentially curative therapies. Consistent with our commitment to bring innovative, safe, and effective therapies to patients, we are focused on conducting the clinical trials necessary to gain regulatory approvals to make our cell therapies broadly available to patients. Participation in one of our clinical trials is the best way to access our investigational therapies.

We encourage patients interested in our investigational therapies to learn more about our ongoing studies by visiting and searching for CARGO Therapeutics. If you are a physician who is interested in learning more about our investigational cell therapies, or participating in our clinical trials, please submit a request to